Is panic disorder a disorder of physical fitness? A heuristic proposal

Perna, Giampaolo; Caldirola, Daniela

doi:10.12688/f1000research.12788.1

Cited by 17 publications

(15 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In conclusion, the ability of OX1R antagonists to decrease hypersensitivity to CO 2 /NaLac (a biomarker of human panic 7 , 16 ) in animal models encouraged future development of these compounds as potential novel treatment for PAs in patients with PD. Although very limited, preliminary clinical findings supported this possibility, suggesting that compounds such as JNJ-61393115 deserve further clinical investigation.…”

Section: Discussionmentioning

confidence: 99%

“… 65–67 These compounds may have potential additional therapeutic effects in PD, acting on conditioned responses and panic-related phobias. 7 , 16 …”

Section: Discussionmentioning

confidence: 99%

“… 13–15 We recently proposed that subtle imbalances in bodily homeostatic global functioning reduce global physical adaptability to internal changes and may lead to PAs. 16 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Experimental Drugs for Panic Disorder: An Updated Systematic Review

Caldirola¹,

Alciati²,

Cuniberti³

et al. 2021

JEP

Self Cite

View full text Add to dashboard Cite

Several effective pharmacological therapies for panic disorder (PD) are available, but they have some drawbacks, and unsatisfactory outcomes can occur. Expanding the variety of anti-panic medications may allow for improving PD treatment. The authors performed an updated systematic review of preclinical and clinical (Phase I–III) pharmacological studies to look for advances made in the last six years concerning novel-mechanism-based anti-panic compounds or using medications approved for nonpsychiatric medical conditions to treat PD. The study included seven published articles presenting a series of preclinical studies, two Phase I clinical studies with orexin receptor (OXR) antagonists, and two clinical studies investigating the effects of D-cycloserine (DCS) and xenon gas in individuals with PD. The latest preclinical findings confirmed and expanded previous promising indications of OXR1 antagonists as novel-mechanism-based anti-panic compounds. Translating preclinical research into clinical applications remains in the early stages. However, limited clinical findings suggested the selective OXR1 antagonist JNJ-61393115 may exert anti-panic effects in humans. Overall, OXR1 antagonists displayed a favorable profile of short-term safety and tolerability. Very preliminary suggestions of possible anti-panic effects of xenon gas emerged but need confirmation with more rigorous methodology. DCS did not seem promising as an enhancer of cognitive-behavioral therapy in PD. Future studies, including objective panic-related physiological parameters, such as respiratory measures, and expanding the use of panic vulnerability biomarkers, such as hypersensitivity to CO 2 panic provocation, may allow for more reliable conclusions about the anti-panic properties of new compounds.

show abstract

Section: Discussionmentioning

confidence: 99%

“… 65–67 These compounds may have potential additional therapeutic effects in PD, acting on conditioned responses and panic-related phobias. 7 , 16 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Experimental Drugs for Panic Disorder: An Updated Systematic Review

Caldirola¹,

Alciati²,

Cuniberti³

et al. 2021

JEP

Self Cite

View full text Add to dashboard Cite

show abstract

“…Rapee [107] had identified hyperventilation and subtle onset of PD at an older age than people presenting with GAD. Panic is characterized by a set of sympathetic autonomic responses that culminate in anticipatory seizures, subjective discomfort and fear of losing control and/or dying [108][109][110][111][112][113][114], whereas GAD can be defined as a clinical condition held from distortions concerning ambiguous situations that are characterized by uncertain consequences [115]. These two clinical conditions exhibit distinct comorbidities.…”

Section: Sample Characteristics and New Approach For Psychometric Pro...mentioning

confidence: 99%

Network analysis applied to DASS-21: Emergence of a new dimension

Alvarenga

Bandeira

Guilhermino

et al. 2022

Preprint

View full text Add to dashboard Cite

The DASS-21 has been studied in different samples and cultures as a brief tool for screening and referral to specialized interventions, thus presenting the prerogative to be characterized as a complex system (CS). CS is a new approach to data analysis assumes that items on a scale are components integrated as a network. Despite this, to date network analysis has not been applied to verify the psychometric properties of the DASS-21. This was a non-clinical sample consisting of college students and professionals (N = 4017), aged 18 years or older (M = 31.16; SD = 10.308), from different Brazilian regions. The data collection was done through electronic forms composed by a sociodemographic questionnaire and DASS-21. Participants could forward the form to other potential respondents. Uni, bi, and multivariate analyses were used, and, among them, exploratory graph analysis (EGA) and boostrap EGA (BootEGA). EGA e BootEGA generated a model with four factors. The four-factor model from DASS-21 showed better fit rates compared to the others replicated in this research. The new four factor model has excellent composite reliability and is invariant regard to gender and type of activity performed. This research was composed of a non-probabilistic and convenience sample, without equitable geographical distribution of the participants and whose answers to this study were provided only by the web-based forms. The DASS-21 presented a new factor model composed of four distinct dimensions with excellent intrinsic features.

show abstract

“…In particular, anticipatory anxiety is known to be an important predictor of quality-of-life changes [47]. Therefore, lowering anticipatory anxiety through a variety of treatments can be an important factor in allowing patients with PD to participate in physical activity [48].…”

Section: Patients With Pd and Barriers To Physical Activitymentioning

confidence: 99%

Understanding the Life, Pain, and Barriers to Physical Activity in Korean Patients with Panic Disorder: Photovoice Inquiry

Kim

Ryu²,

Chung

et al. 2021

IJERPH

View full text Add to dashboard Cite

Purpose: This study attempted to understand the life, pain, and barriers to physical activity in the daily life of patients with panic disorder (PD). It aimed to provide specific evidence to promote physical activity for patients, suggesting that suitable physical activity strategies for patients with PD would be of value. Methods: Seven patients were invited to participate in a photovoice study. Photovoice is one example of participatory action research. Results: This study inductively identified two main themes: the life and pain of patients with PD and perceived barriers to participate in physical activity by patients with panic disorder. Conclusion: Based on a specific understanding of the population, this study attempted to provide evidence why patients with panic disorder need appropriate physical-activity-promoting strategies.

show abstract

Is panic disorder a disorder of physical fitness? A heuristic proposal

Cited by 17 publications

References 118 publications

Experimental Drugs for Panic Disorder: An Updated Systematic Review

Experimental Drugs for Panic Disorder: An Updated Systematic Review

Network analysis applied to DASS-21: Emergence of a new dimension

Understanding the Life, Pain, and Barriers to Physical Activity in Korean Patients with Panic Disorder: Photovoice Inquiry

Contact Info

Product

Resources

About